192 related articles for article (PubMed ID: 33399070)
21. Prevalence of Pathogenic Germline
Abe A; Imoto I; Tange S; Nishimura M; Iwasa T
Genes (Basel); 2022 Jun; 13(6):. PubMed ID: 35741847
[TBL] [Abstract][Full Text] [Related]
22. The benefit of pancreatic cancer surveillance in carriers of germline BRCA1/2 pathogenic variants.
Laish I; Schechter M; Dancour A; Lieberman S; Levi Z; Goldberg Y; Kedar I; Hasnis E; Half E; Levi GR; Katz L; Vainer ED; Genzel D; Aharoni M; Chen-Shtoyerman R; Abu-Freha N; Raitses-Gurevich M; Golan T; Bernstein-Molho R; Ben Yehoyada M; Gluck N; Rosner G
Cancer; 2024 Jan; 130(2):256-266. PubMed ID: 37861363
[TBL] [Abstract][Full Text] [Related]
23. Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomes.
Momtaz P; O'Connor CA; Chou JF; Capanu M; Park W; Bandlamudi C; Berger MF; Kelsen DP; Suehnholz SP; Chakravarty D; Yu KH; Varghese AM; Zervoudakis A; Li J; Ku GY; Park JS; Shcherba M; Harding JJ; Goldberg Z; Abou-Alfa GK; Salo-Mullen EE; Stadler ZK; Iacobuzio-Donahue CA; O'Reilly EM
Cancer; 2021 Dec; 127(23):4393-4402. PubMed ID: 34351646
[TBL] [Abstract][Full Text] [Related]
24. Are BRCA1 and BRCA2 gene mutation patients underscreened for pancreatic adenocarcinoma?
Roch AM; Schneider J; Carr RA; Lancaster WP; House MG; Zyromski NJ; Nakeeb A; Schmidt CM; Ceppa EP
J Surg Oncol; 2019 May; 119(6):777-783. PubMed ID: 30636051
[TBL] [Abstract][Full Text] [Related]
25. Clinical Characteristics and Exploratory Genomic Analyses of Germline BRCA1 or BRCA2 Mutations in Breast Cancer.
Park S; Lee E; Park S; Lee S; Nam SJ; Kim SW; Lee JE; Yu JH; Kim JY; Ahn JS; Im YH; Park WY; Park K; Park YH
Mol Cancer Res; 2020 Sep; 18(9):1315-1325. PubMed ID: 32554602
[TBL] [Abstract][Full Text] [Related]
26. Prevalence of germline pathogenic
Morgan RD; Burghel GJ; Flaum N; Bulman M; Clamp AR; Hasan J; Mitchell CL; Schlecht H; Woodward ER; Lallo FI; Crosbie EJ; Edmondson RJ; Wallace AJ; Jayson GC; Evans DGR
J Med Genet; 2019 May; 56(5):301-307. PubMed ID: 30683677
[TBL] [Abstract][Full Text] [Related]
27. The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers.
Iqbal J; Ragone A; Lubinski J; Lynch HT; Moller P; Ghadirian P; Foulkes WD; Armel S; Eisen A; Neuhausen SL; Senter L; Singer CF; Ainsworth P; Kim-Sing C; Tung N; Friedman E; Llacuachaqui M; Ping S; Narod SA;
Br J Cancer; 2012 Dec; 107(12):2005-9. PubMed ID: 23099806
[TBL] [Abstract][Full Text] [Related]
28. The role of PARP inhibitors in germline BRCA-associated pancreatic ductal adenocarcinoma.
Moffat GT; O'Reilly EM
Clin Adv Hematol Oncol; 2020 Mar; 18(3):168-179. PubMed ID: 32609666
[TBL] [Abstract][Full Text] [Related]
29. BRCA1 and BRCA2 mutations and clinical interpretation in 398 ovarian cancer patients: comparison with breast cancer variants in a similar population.
Cardoso FC; Goncalves S; Mele PG; Liria NC; Sganga L; Diaz Perez I; Podesta EJ; Solano AR
Hum Genomics; 2018 Aug; 12(1):39. PubMed ID: 30103829
[TBL] [Abstract][Full Text] [Related]
30. The first Japanese nationwide multicenter study of
Enomoto T; Aoki D; Hattori K; Jinushi M; Kigawa J; Takeshima N; Tsuda H; Watanabe Y; Yoshihara K; Sugiyama T
Int J Gynecol Cancer; 2019 Jul; 29(6):1043-1049. PubMed ID: 31263023
[TBL] [Abstract][Full Text] [Related]
31. Clinical characterization of patients with gBRCA1/2 mutation-positive unresectable pancreatic cancer: a multicenter prospective study.
Kubo T; Muramatsu J; Arihara Y; Murota A; Ishikawa K; Yoshida M; Nagashima H; Tamura F; Ikeda Y; Usami M; Ono M; Nakamura H; Watanabe D; Shibata T; Kasahara K; Sakurai A; Takada K
Jpn J Clin Oncol; 2024 Jan; 54(1):47-53. PubMed ID: 37791389
[TBL] [Abstract][Full Text] [Related]
32. Prevalence of mutations in BRCA and homologous recombination repair genes and real-world standard of care of Asian patients with HER2-negative metastatic breast cancer starting first-line systemic cytotoxic chemotherapy: subgroup analysis of the global BREAKOUT study.
Koh SJ; Ohsumi S; Takahashi M; Fukuma E; Jung KH; Ishida T; Dai MS; Chang CH; Dalvi T; Walker G; Bennett J; O'Shaughnessy J; Balmaña J
Breast Cancer; 2022 Jan; 29(1):92-102. PubMed ID: 34467476
[TBL] [Abstract][Full Text] [Related]
33. An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions.
Lowery MA; Kelsen DP; Stadler ZK; Yu KH; Janjigian YY; Ludwig E; D'Adamo DR; Salo-Mullen E; Robson ME; Allen PJ; Kurtz RC; O'Reilly EM
Oncologist; 2011; 16(10):1397-402. PubMed ID: 21934105
[TBL] [Abstract][Full Text] [Related]
34.
Rosen MN; Goodwin RA; Vickers MM
World J Gastroenterol; 2021 May; 27(17):1943-1958. PubMed ID: 34007132
[TBL] [Abstract][Full Text] [Related]
35. Hematologic toxicities of chemotherapy in breast and ovarian cancer patients carrying BRCA1/BRCA2 germline pathogenic variants. A single center experience and review of the literature.
Hu-Heimgartner K; Lang N; Ayme A; Ming C; Combes JD; Chappuis VN; Vazquez C; Friedlaender A; Vuilleumier A; Bodmer A; Viassolo V; Sandoval JL; Chappuis PO; Labidi-Galy SI
Fam Cancer; 2023 Jul; 22(3):283-289. PubMed ID: 37119509
[TBL] [Abstract][Full Text] [Related]
36. Outcome of Pancreatic Cancer Surveillance Among High-Risk Individuals Tested for Germline Mutations in
Saldia A; Olson SH; Nunes P; Liang X; Samson ML; Salo-Mullen E; Marcell V; Stadler ZK; Allen PJ; Offit K; Kurtz RC
Cancer Prev Res (Phila); 2019 Sep; 12(9):599-608. PubMed ID: 31337648
[TBL] [Abstract][Full Text] [Related]
37. Association of gBRCA1/2 mutation locations with ovarian cancer risk in Japanese patients from the CHARLOTTE study.
Yoshihara K; Enomoto T; Aoki D; Watanabe Y; Kigawa J; Takeshima N; Inomata H; Hattori K; Jinushi M; Tsuda H; Sugiyama T
Cancer Sci; 2020 Sep; 111(9):3350-3358. PubMed ID: 32495382
[TBL] [Abstract][Full Text] [Related]
38. Brain Metastases in Pancreatic Ductal Adenocarcinoma: Assessment of Molecular Genotype-Phenotype Features-An Entity With an Increasing Incidence?
Jordan EJ; Lowery MA; Basturk O; Allen PJ; Yu KH; Tabar V; Beal K; Reidy DL; Yamada Y; Janjigian Y; Abou-Alfa GK; O'Reilly EM
Clin Colorectal Cancer; 2018 Jun; 17(2):e315-e321. PubMed ID: 29496399
[TBL] [Abstract][Full Text] [Related]
39. Mutations of TP53 and genes related to homologous recombination repair in breast cancer with germline BRCA1/2 mutations.
Kim J; Jeong K; Jun H; Kim K; Bae JM; Song MG; Yi H; Park S; Woo GU; Lee DW; Kim TY; Lee KH; Im SA
Hum Genomics; 2023 Jan; 17(1):2. PubMed ID: 36604691
[TBL] [Abstract][Full Text] [Related]
40. Cost-utility analysis of germline BRCA1/2 testing in women with high-grade epithelial ovarian cancer in Spain.
Moya-Alarcón C; González-Domínguez A; Simon S; Pérez-Román I; González-Martín A; Bayo-Lozano E; Sánchez-Heras AB
Clin Transl Oncol; 2019 Aug; 21(8):1076-1084. PubMed ID: 30617925
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]